Pharmaceutical News

RSS

Foreign legislation strongly influences domestic novel psychoactive substance deaths

Ric Treble is a retired forensic chemist, who has studied the development of novel drugs for over thirty years.

30 Jan 2026

Antidepressant use does not worsen early outcomes after traumatic brain injury

Taking certain antidepressants at the time of a traumatic brain injury (TBI) is not associated with an increased risk of death, brain surgery or longer hospital stays, according to a study published on January 28, 2026, in Neurology, the medical journal of the American Academy of Neurology.

28 Jan 2026

Research finds scientists view ELNs as “glorified filing cabinets,” driving frustration, duplication and shadow AI use

Sapio Sciences, the science-aware™ AI lab informatics platform, today announced the results of new research examining scientists’ sentiment around electronic lab notebooks (ELNs) and AI tools in modern laboratory environments.

From Sapio Sciences 27 Jan 2026

Urate-lowering gout treatment can reduce the risk of heart attack and stroke

A groundbreaking new study, led by experts at the University of Nottingham, has found that medicines used to treat gout can also reduce the risk of heart attack and stroke in people with gout.

27 Jan 2026

Why exercise is essential for restoring fitness after GLP-1-based weight loss

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, improves physical function and cardiorespiratory fitness after diet-induced weight loss in adults with obesity. In contrast, liraglutide alone sustains weight loss but does not significantly improve measured physical fitness outcomes.

26 Jan 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has recently received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA), intended for the treatment of Parkinson's Disease.

23 Jan 2026

FDA warns consumers about fake cancer cures sold online

Beware of products claiming to cure cancer on websites or social media platforms, such as Facebook and Instagram. According to Nicole Kornspan, M.P.H., a consumer safety officer at the U.S. Food and Drug Administration (FDA), they're rampant these days.

22 Jan 2026

Menopausal hormone therapy linked to greater weight loss with tirzepatide

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity.

22 Jan 2026

High-dose inhaled nitric oxide could fight multidrug-resistant infections

Overuse of antibiotics has accelerated the development of bacterial resistance to conventional drugs, a global health crisis projected to result in more than 10 million deaths annually by 2050.

21 Jan 2026

Long-term proton pump inhibitor use not linked to stomach cancer

The long term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased risk of developing gastric (stomach) cancer, finds a study of Nordic health data published by The BMJ today.

21 Jan 2026

GLP-1 weight-loss drugs show early promise for treating addiction

This systematic review evaluates preclinical and clinical evidence on glucagon-like peptide-1 receptor agonists as potential treatments for substance use disorders. Findings show consistent reductions in drug- and alcohol-seeking behaviors in animal models, while human evidence remains limited, heterogeneous, and preliminary.

21 Jan 2026

Shingles vaccination is linked to slower biological aging in older adults

This population-based study of U.S. adults aged 70 and older found that shingles vaccination was associated with slower epigenetic and transcriptomic aging, as well as lower systemic inflammation. No significant associations were observed for neurodegeneration or cardiovascular biomarkers, highlighting domain-specific molecular effects rather than broad clinical changes.

21 Jan 2026

Study finds no safety or efficacy gap between paracetamol and ibuprofen for neonatal PDA

In a UK pilot randomized trial, intravenous paracetamol and ibuprofen showed no statistically significant differences in short-term efficacy or safety when used as rescue therapy for hemodynamically significant patent ductus arteriosus in very preterm infants. The study demonstrated high feasibility but was not powered to determine clinical superiority or equivalence between treatments.

21 Jan 2026

Study examines potential impact of the Medicare Prescription Payment Plan on cancer patients

A new study examines the potential impact of the Medicare Prescription Payment Plan (M3P) - an opt-in policy implemented in 2025 under the Inflation Reduction Act that allows beneficiaries to spread out of pocket (OOP) costs over the calendar year - on Medicare Part D beneficiaries with cancer who face high out-of-pocket (OOP) prescription drug costs.

19 Jan 2026